Admatop 2.5 Injection
Marketer
Admac Pharma Ltd
Salt Composition
Topotecan (1.0mg/ml)
Overview Admatop 2.5 Injection
Ovarian cancer treatment utilizes Admatop 2.5 Injection, which inhibits or reduces cancerous cell proliferation. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your condition and may vary. Strict adherence to your doctor's instructions is crucial, as incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may take weeks or months to manifest; discontinue only under medical guidance. Common side effects encompass fatigue, nausea, vomiting, weakness, and abdominal discomfort. A decreased blood cell count (including red and white blood cells), increasing infection risk, is a potential consequence. Report fever, chills, sore throat, or severe diarrhea immediately. Regular blood tests monitoring blood cell counts, as well as heart, liver, and uric acid levels, are necessary. Pre-treatment disclosure of any heart, liver, or kidney conditions, alongside all current medications (especially those combating infections), is essential due to potential drug interactions. This injection is contraindicated during pregnancy and lactation. Reliable contraception for both partners is vital throughout treatment to prevent conception.
Uses of Admatop 2.5 Injection
Cancer of the ovaries
Major Benefits of Admatop 2.5 Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Admatop 2.5 Injection:
- Tiredness
- Vomiting
- Weakness
- Nausea
- Abdominal pain
- Indigestion
- Decreased white blood cell count
- Decreased blood cells (red cells, white cells, and platelets)
- Diarrhea
- Injection site reactions (pain, swelling, redness)
How to use Admatop 2.5 Injection:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Admatop 2.5 Injection works:
Admatop 2.5 Injection is a cancer treatment that inhibits topoisomerase I, a key enzyme in cancer cell DNA replication. This inhibition reduces cancerous cell proliferation, ultimately leading to their demise.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions from combining Admatop 2.5 Injection and alcohol.
PregnancyCONSULT YOUR DOCTOR
Administering Admatop 2.5 Injection during pregnancy poses a confirmed risk to fetal development, rendering it unsafe. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingUNSAFE
Lactation is contraindicated with Admatop 2.5 Injection due to potential infant toxicity.
DrivingUNSAFE
Admatop 2.5 Injection may induce adverse reactions that impair driving ability. Fatigue is a potential side effect of Admatop 2.5 Injection, potentially affecting driving safety.
KidneyCAUTION
Admatop 2.5 Injection requires careful administration in individuals with impaired kidney function; dosage modification may be necessary. Physician consultation is advised. Admatop 2.5 Injection is contraindicated for patients experiencing end-stage renal disease.
LiverSAFE IF PRESCRIBED
Admatop 2.5 Injection poses no safety concerns for individuals with hepatic impairment; no dosage modification is necessary.
What if you forget to take Admatop 2.5 Injection :
Forgetting a dose of Admatop 2.5 Injection? Seek medical advice immediately.
Facts to Know About Admatop 2.5 Injection
| Label | Value |
|---|---|
| Type of Compound | Topoisomerase I inhibitor |
| Addictive | None. |
| Medication Category | Cancer-fighting drugs |
| Mechanism of Action | DNA Topoisomerase Targeting Agent |
3,018 People bought this recently